Straits Times Index
3,230.55 +21.37 (+0.67%) Nikkei
26,781.68 +176.84 (+0.66%) Hang Seng
20,697.36 +581.16 (+2.89%) FTSE 100
7,585.46 +20.54 (+0.27%) BTC-USD
28,875.14 +182.58 (+0.64%) CMC Crypto 200
625.79 -3.71 (-0.59%)
Illumina, Inc. (ILMN)
After hours:
| Previous close | 243.57 |
| Open | 245.88 |
| Bid | 248.00 x 1000 |
| Ask | 260.00 x 1100 |
| Day's range | 244.43 - 258.07 |
| 52-week range | 208.35 - 526.00 |
| Volume | |
| Avg. volume | 956,269 |
| Market cap | 40.541B |
| Beta (5Y monthly) | 0.99 |
| PE ratio (TTM) | 56.65 |
| EPS (TTM) | 4.55 |
| Earnings date | 03 Aug 2022 - 08 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 358.56 |
- Reuters
EU court to rule July 13 on Illumina challenge of EU review of Grail -sources
A European court will decide on July 13 whether U.S. life sciences company Illumina's $8 billion cash-and-stock takeover of Grail should be scrutinised by EU antitrust regulators, people familiar with the matter said on Wednesday. The case coincides with the European Commission seeking to expand its power to examine big companies' acquisitions of start-ups aimed at shutting down nascent rivals, with the focus on tech and pharma deals. The Luxembourg-based General Court, Europe's second-top court, declined to comment on the date of its ruling.
- Zacks
Illumina (ILMN) to Offer Companion Diagnostic for VITRAKVI
Illumina's (ILMN) first companion diagnostic claim for TSO Comprehensive (EU) will help identify cancer patients with NTRK gene fusions for a genomically matched treatment.
- Zacks
Illumina's (ILMN) Innovations Drive Growth, Cost Woes Linger
Illumina (ILMN) is working on its goals to strengthen its foothold in the multi-billion gene sequencing market with some highly competitive products in its existing portfolio and pipeline.
